Urgent Action Needed To End Tuberculosis By 2030, Concludes WHO’s Global Tuberculosis Report 14/10/2020 Svĕt Lustig Vijay The world must take urgent action to end the global tuberculosis epidemic by 2030, especially as the pandemic threatens to unwind hard-won progress made in past decades, concluded the WHO’s 2020 Global Tuberculosis Report on Wednesday. While the WHO European region is on track to achieve key 2020 targets, the rest of the world has […] Continue reading -> Moderna Makes Milestone Pledge To “Not Enforce Our Patents” On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward 08/10/2020 Raisa Santos & Elaine Ruth Fletcher Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period. “We feel […] Continue reading -> US Food and Drug Administration Issues New Rules Likely To Delay COVID-19 Vaccine Approval Until After Presidential Election 07/10/2020 Elaine Ruth Fletcher Acting on the advice of experts, the United States Food and Drug Administration on Tuesday issued new safety-focused guidelines for approval of new COVID-19 vaccines, that would almost certainly delay their emergency approval until after the November Presidential elections. Just hours after the rules were issued, United States President Donald Trump accused the FDA of […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> WHO Announces High Level Review Of Its Emergency Response Capacity 27/08/2020 Svĕt Lustig Vijay The World Health Organization will establish a new high level review of the Organization’s capacity to respond todisease outbreaks in the framework of the International Health Regulations (IHR) that govern emergency response. The aim is to ensure that WHO is “as effective as possible in operations as they unfold,” announced Director-General Dr. Tedros Adhanom Ghebreyesus […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Moderna Makes Milestone Pledge To “Not Enforce Our Patents” On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward 08/10/2020 Raisa Santos & Elaine Ruth Fletcher Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period. “We feel […] Continue reading -> US Food and Drug Administration Issues New Rules Likely To Delay COVID-19 Vaccine Approval Until After Presidential Election 07/10/2020 Elaine Ruth Fletcher Acting on the advice of experts, the United States Food and Drug Administration on Tuesday issued new safety-focused guidelines for approval of new COVID-19 vaccines, that would almost certainly delay their emergency approval until after the November Presidential elections. Just hours after the rules were issued, United States President Donald Trump accused the FDA of […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> WHO Announces High Level Review Of Its Emergency Response Capacity 27/08/2020 Svĕt Lustig Vijay The World Health Organization will establish a new high level review of the Organization’s capacity to respond todisease outbreaks in the framework of the International Health Regulations (IHR) that govern emergency response. The aim is to ensure that WHO is “as effective as possible in operations as they unfold,” announced Director-General Dr. Tedros Adhanom Ghebreyesus […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
US Food and Drug Administration Issues New Rules Likely To Delay COVID-19 Vaccine Approval Until After Presidential Election 07/10/2020 Elaine Ruth Fletcher Acting on the advice of experts, the United States Food and Drug Administration on Tuesday issued new safety-focused guidelines for approval of new COVID-19 vaccines, that would almost certainly delay their emergency approval until after the November Presidential elections. Just hours after the rules were issued, United States President Donald Trump accused the FDA of […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> WHO Announces High Level Review Of Its Emergency Response Capacity 27/08/2020 Svĕt Lustig Vijay The World Health Organization will establish a new high level review of the Organization’s capacity to respond todisease outbreaks in the framework of the International Health Regulations (IHR) that govern emergency response. The aim is to ensure that WHO is “as effective as possible in operations as they unfold,” announced Director-General Dr. Tedros Adhanom Ghebreyesus […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> WHO Announces High Level Review Of Its Emergency Response Capacity 27/08/2020 Svĕt Lustig Vijay The World Health Organization will establish a new high level review of the Organization’s capacity to respond todisease outbreaks in the framework of the International Health Regulations (IHR) that govern emergency response. The aim is to ensure that WHO is “as effective as possible in operations as they unfold,” announced Director-General Dr. Tedros Adhanom Ghebreyesus […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO, The Pandemic And Europe’s New Global Health Leadership Role 29/09/2020 Elaine Ruth Fletcher Billions of dollars in vaccine investments are needed to beat back Covid-19. But on the bright side, Europe is playing a more active global health leadership role. Geneva’s ‘dean’ of global health speaks to Geneva Solutions ahead of Wednesday’s opening of the European Health Forum (Gastein), which brings together key policymakers and experts from across […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> WHO Announces High Level Review Of Its Emergency Response Capacity 27/08/2020 Svĕt Lustig Vijay The World Health Organization will establish a new high level review of the Organization’s capacity to respond todisease outbreaks in the framework of the International Health Regulations (IHR) that govern emergency response. The aim is to ensure that WHO is “as effective as possible in operations as they unfold,” announced Director-General Dr. Tedros Adhanom Ghebreyesus […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> WHO Announces High Level Review Of Its Emergency Response Capacity 27/08/2020 Svĕt Lustig Vijay The World Health Organization will establish a new high level review of the Organization’s capacity to respond todisease outbreaks in the framework of the International Health Regulations (IHR) that govern emergency response. The aim is to ensure that WHO is “as effective as possible in operations as they unfold,” announced Director-General Dr. Tedros Adhanom Ghebreyesus […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Announces High Level Review Of Its Emergency Response Capacity 27/08/2020 Svĕt Lustig Vijay The World Health Organization will establish a new high level review of the Organization’s capacity to respond todisease outbreaks in the framework of the International Health Regulations (IHR) that govern emergency response. The aim is to ensure that WHO is “as effective as possible in operations as they unfold,” announced Director-General Dr. Tedros Adhanom Ghebreyesus […] Continue reading -> Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Coronavirus Reinfection – Can You Really Get It Again? The Impacts For A Second Wave & Vaccine Development 27/08/2020 Svĕt Lustig Vijay This Tuesday, European researchers documented two new cases of COVID-19 reinfection, just a day after the first genetically proven case of reinfection was reported in a 33-year old man in Hong Kong. The 33-year old had contracted two genetically distinct strains of Covid-19 over a period of four and a half months. The potential for […] Continue reading -> Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Evidence On Convalescent Plasma Therapy To Treat COVID-19 Patients Is “Very Low Quality”, Warns WHO 24/08/2020 Svĕt Lustig Vijay & Elaine Ruth Fletcher There is insufficient evidence that treating people hospitalized for COVID-19 with blood plasma from recovered patients is safe and effective – and more randomized clinical trials are thus needed, warned the World Health Organization on Monday. Evidence overall remains “inconclusive,” said WHO chief scientist Soumya Swaminathan at a WHO press conference on Monday. She spoke […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts